0001140361-23-059159.txt : 20231222 0001140361-23-059159.hdr.sgml : 20231222 20231222161531 ACCESSION NUMBER: 0001140361-23-059159 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231222 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 231509977 BUSINESS ADDRESS: STREET 1: ROUTE 206 AND PROVINCE LINE ROAD CITY: PRINCETON STATE: NJ ZIP: 08543 BUSINESS PHONE: 6092524621 MAIL ADDRESS: STREET 1: ROUTE 206 AND PROVINCE LINE ROAD CITY: PRINCETON STATE: NJ ZIP: 08543 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 ef20017313_8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2023


BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)


Delaware
001-01136
22-0790350
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)

Route 206 & Province Line Road
Princeton, New Jersey, 08543
(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (609) 252-4621


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.10 Par Value
   BMY  
New York Stock Exchange
1.000% Notes due 2025
  
BMY25
  
New York Stock Exchange
1.750% Notes due 2035
  
BMY35
  
New York Stock Exchange
Celgene Contingent Value Rights
  
CELG RT
  
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.
 
On December 22, 2023, Bristol-Myers Squibb Company (“BMS”), and Karuna Therapeutics, Inc. (“Karuna”), issued a joint press release announcing that BMS, Karuna and Miramar Merger Sub Inc., a wholly owned subsidiary of BMS (“Merger Sub”), have signed an agreement and plan of merger (the “Merger Agreement”) providing that, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Karuna, with Karuna surviving as a wholly owned subsidiary of BMS (the “Merger”). In the Merger, each share of Karuna common stock issued and outstanding immediately prior to the effective time of the Merger (other than certain excluded shares as described in the Merger Agreement) will automatically be converted into the right to receive $330.00 in cash, without interest, and subject to any required withholding taxes. A copy of the joint press release announcing the Merger is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
 
Additional Information and Where to Find it
 
In connection with the proposed acquisition of Karuna by BMS, Karuna intends to file a preliminary and definitive proxy statement. The definitive proxy statement and proxy card will be delivered to the stockholders of Karuna in advance of the special meeting relating to the proposed acquisition. This report is not a substitute for the proxy statement or any other document that may be filed by Karuna with the U.S. Securities and Exchange Commission (the “SEC”). KARUNA’S STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF BMS AND KARUNA WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES TO THE PROPOSED ACQUISITION. Investors and security holders will be able to obtain a free copy of the proxy statement and such other documents containing important information about BMS and Karuna, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. BMS and Karuna make available free of charge at BMS’ website at www.bms.com/investors and Karuna’s website at www.investors.karunatx.com, respectively, copies of materials they file with, or furnish to, the SEC.
 
Participants in the Solicitation
 
This report does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any securities. BMS, Karuna and their respective directors, executive officers and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of Karuna in connection with the proposed acquisition. Information regarding BMS’ directors and executive officers is contained in BMS’ Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 14, 2023, and its definitive proxy statement for the 2023 annual meeting of stockholders, which was filed with the SEC on March 23, 2023. Information regarding Karuna’s directors and executive officers is contained in Karuna’s definitive proxy statement for the 2023 annual meeting of stockholders, which was filed with the SEC on April 27, 2023. To the extent holdings of BMS’ or Karuna’s securities by their respective directors or executive officers have changed since the amounts set forth in such 2023 proxy statements, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be included in the definitive proxy statement relating to the proposed acquisition when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, BMS’ website at www.bms.com and Karuna’s website at www.karunatx.com.
 
Cautionary Statement Regarding Forward-Looking Statements
 
This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the proposed acquisition of Karuna by BMS, the expected timetable for completing the transaction, future opportunities for the combined businesses, the expected benefits of BMS’ acquisition of Karuna and the development and commercialization of Karuna’s product candidates, including the therapeutic and commercial potential of KarXT and Karuna’s other technologies and products in development. These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them, that are difficult to predict, may be beyond our control and could cause actual outcomes and results to differ materially from those expressed in, or implied by, the forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the approval of Karuna’s stockholders of the proposed acquisition, which may be delayed or may not be obtained, (ii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iii) the risk that legal proceedings may be instituted related to the Merger Agreement, (iv) any competing offers or acquisition proposals for Karuna, (v) the possibility that various conditions to the consummation of the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed acquisition, including the response of business partners and competitors to the announcement of the proposed acquisition or difficulties in employee retention as a result of the announcement and pendency of the proposed acquisition. The actual financial impact of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this report should be evaluated together with the many risks and uncertainties that affect BMS’ business and market, particularly those identified in the cautionary statement and risk factors discussion in BMS’ Annual Report on Form 10-K for the year ended December 31, 2022, and Karuna’s business, particularly those identified in the risk factors discussion in Karuna’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other documents that may be filed by BMS or Karuna from time to time with the SEC. Neither BMS nor Karuna undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. The forward-looking statements made in this report relate only to events as of the date on which the statements are made and readers are cautioned not to place undue reliance on such statements.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
The following exhibits are included as part of this Current Report on Form 8-K:
 
Exhibit No.
  
Description
99.1
  
Joint Press Release of Bristol-Myers Squibb Company and Karuna Therapeutics, Inc., dated December 22, 2023.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit No.
  
Description
 
Joint Press Release of Bristol-Myers Squibb Company and Karuna Therapeutics, Inc., dated December 22, 2023.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
   
Dated: December 22, 2023
By:
/s/ Kimberly M. Jablonski
 
Name:
Kimberly M. Jablonski
 
Title:
Corporate Secretary


EX-99.1 2 ef20017313_ex99-1.htm JOINT PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY AND KARUNA THERAPEUTICS, INC.
Exhibit 99.1

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety

KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications

KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024

Bristol Myers Squibb to Host a Conference Call Today at 8:00 a.m. ET

PRINCETON, N.J. & BOSTON, M.A. – December 22, 2023 – Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.

Karuna is a biopharmaceutical company driven to discover, develop and deliver transformative medicines for people living with psychiatric and neurological conditions. Karuna’s lead asset, KarXT (xanomeline-trospium), is an antipsychotic with a novel mechanism of action (MoA) and differentiated efficacy and safety. Karuna’s New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults was accepted for review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. KarXT is also in registrational trials both for adjunctive therapy to existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer’s disease. Bristol Myers Squibb believes KarXT represents a significant revenue contribution opportunity. Bristol Myers Squibb also sees potential from Karuna’s early-stage and pre-clinical pipeline.

“There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space. We expect KarXT to enhance our growth through the late 2020s and into the next decade,” said Christopher Boerner, Ph.D., Chief Executive Officer of Bristol Myers Squibb. “This transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need. We look forward to welcoming the talented Karuna team to Bristol Myers Squibb.”

“Schizophrenia and Alzheimer’s disease psychosis affect millions of people worldwide, with limited to no treatment options. KarXT’s novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile,” said Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. “KarXT also has the potential to deliver meaningful benefits to patients as an adjunctive treatment for patients with schizophrenia and as a first treatment for Alzheimer’s disease psychosis.”

Bill Meury, President and Chief Executive Officer of Karuna Therapeutics, said, “Karuna’s portfolio offers advancements in treatment not seen in many years. With Bristol Myers Squibb’s long-standing expertise in developing and commercializing medicines on a global scale and legacy in neuroscience, KarXT and the other assets in our pipeline will be well-positioned to reach those living with schizophrenia and Alzheimer’s disease psychosis. This announcement is a testament to the Karuna team’s talent, hard work, and innovation.”

Delivering Meaningful Benefits to Patients with KarXT

KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. KarXT has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments, including no meaningful weight gain, extrapyramidal symptoms, increased prolactin levels, akathisia and/or sedation.

Given this differentiated profile, KarXT has meaningful and expanding revenue potential in schizophrenia and with upside in additional indications and geographies:


 •
Schizophrenia: KarXT is expected to launch in late 2024 in the U.S. as a treatment for schizophrenia in adults. There are approximately 1.6 million1 people treated for schizophrenia in the U.S., a significant portion of whom do not respond to currently available therapies and experience unacceptable side effects.
 

 •
Adjunctive schizophrenia: A registrational clinical trial is currently underway evaluating KarXT as adjunctive treatment with current standard of care agents for the treatment of schizophrenia, with data expected in 2025.


•
Alzheimer’s disease psychosis: Registrational clinical trials are currently underway evaluating KarXT for the treatment of Alzheimer’s disease psychosis, with data expected in 2026. There are more than 6 million2 people living with Alzheimer’s disease in the U.S. There are currently no approved treatments for Alzheimer’s disease psychosis.
 

 •
Additional indications: Bristol Myers Squibb believes KarXT also has potential in additional indications, including Bipolar I disorder, which impacts approximately 1.4 million1 people in the U.S., and Alzheimer’s disease agitation.

The transaction is expected to be dilutive to Bristol Myers Squibb’s non-GAAP diluted earnings per share by approximately $0.30 in 2024 from the financing cost of the transaction, as Bristol Myers Squibb expects to offset the operational expenses of the transaction through continued resource allocation, cost efficiencies and portfolio prioritization. The accounting treatment as a business combination or asset acquisition will be determined upon the expected close of the transaction. Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance. Bristol Myers Squibb’s cash flows and strong financial profile enable continued commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions to shareholders through ongoing dividends and share repurchases.

Transaction Terms and Financing

Under the terms of the merger agreement, Bristol Myers Squibb will acquire all outstanding shares of Karuna common stock for $330.00 per share in cash representing an approximately 53.4% premium to Karuna Therapeutic’s closing stock price on December 21, 2023, for a total equity value of approximately $14.0 billion, or $12.7 billion net of estimated cash acquired.

1 Source: DRG – Clarivate, as of July 2023.
2 Source: “Alzheimer’s Disease Association Facts and Figures,” 2023.

The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including approval of Karuna stockholders and receipt of required regulatory approvals.

Conference Call Information

Bristol Myers Squibb will host a conference call today, Friday, December 22, 2023, at 8:00 a.m. ET during which company executives will review discuss the transaction and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com.

Investors and the public can register for the live conference call here. Those unable to register can access the live conference call by dialing in the U.S. toll-free 1-866-777-2509 or international +1 412-317-5413. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.

A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. A replay of the conference call will be available beginning at 11:30 a.m. ET on December 22, 2023, through 11:30 a.m. ET on January 4, 2024, by dialing in the U.S. toll free 1-877-344-7529 or international +1 412-317-0088, confirmation code: 3194180.

Advisors

Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel. Goldman Sachs & Co. LLC is serving as exclusive financial advisor to Karuna, and Simpson Thacher & Bartlett LLP is serving as legal counsel.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

About Karuna Therapeutics

Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.

Additional Information and Where to Find It

In connection with the proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb, Karuna Therapeutics intends to file a preliminary and definitive proxy statement. The definitive proxy statement and proxy card will be delivered to the stockholders of Karuna Therapeutics in advance of the special meeting relating to the proposed acquisition. This press release is not a substitute for the proxy statement or any other document that may be filed by Karuna Therapeutics with the SEC. KARUNA THERAPEUTICS’ STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF BRISTOL MYERS SQUIBB AND KARUNA THERAPEUTICS WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES TO THE PROPOSED ACQUISITION. Investors and security holders will be able to obtain a free copy of the proxy statement and such other documents containing important information about Bristol Myers Squibb and Karuna Therapeutics, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Bristol Myers Squibb and Karuna Therapeutics make available free of charge at Bristol Myers Squibb’s website at www.bms.com/investors and Karuna Therapeutics’ website at https://karunatx.com/, respectively, copies of materials they file with, or furnish to, the SEC.

Participants in the Solicitation

This press release does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any securities. Bristol Myers Squibb, Karuna Therapeutics and their respective directors, executive officers and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of Karuna Therapeutics in connection with the proposed acquisition. Information regarding Bristol Myers Squibb’s directors and executive officers is contained in Bristol Myer Squibb’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 14, 2023, and its definitive proxy statement for the 2023 annual meeting of stockholders, which was filed with the SEC on March 23, 2023. Information regarding Karuna Therapeutics’ directors and executive officers is contained in Karuna Therapeutics’ definitive proxy statement for the 2023 annual meeting of stockholders, which was filed with the SEC on April 27, 2023. To the extent holdings of Bristol Myers Squibb’s or Karuna Therapeutics’ securities by their respective directors or executive officers have changed since the amounts set forth in such 2023 proxy statements, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be included in the definitive proxy statement relating to the proposed acquisition when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, Bristol Myers Squibb’s website at www.bms.com and Karuna Therapeutics’ website at https://karunatx.com/.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb, the expected timetable for completing the transaction, future opportunities for the combined businesses, the expected benefits of Bristol Myers Squibb’s acquisition of Karuna Therapeutics and the development and commercialization of Karuna Therapeutics’ product candidates, including the therapeutic and commercial potential of KarXT and Karuna Therapeutics’ other technologies and products in development. These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them, that are difficult to predict, may be beyond our control and could cause actual outcomes and results to differ materially from those expressed in, or implied by, the forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the approval of Karuna Therapeutics’ stockholders of the proposed acquisition, which may be delayed or may not be obtained, (ii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iii) the risk that legal proceedings may be instituted related to the merger agreement, (iv) any competing offers or acquisition proposals for Karuna Therapeutics, (v) the possibility that various conditions to the consummation of the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed acquisition, including the response of business partners and competitors to the announcement of the proposed acquisition or difficulties in employee retention as a result of the announcement and pendency of the proposed acquisition. The actual financial impact of this transaction may differ from the expected financial impact described in this press release. In addition, the compounds described in this press release are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2022, and Karuna Therapeutics’ business, particularly those identified in the risk factors discussion in Karuna Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2022, as well as other documents that may be filed by Bristol Myers Squibb or Karuna Therapeutics from time to time with the SEC. Neither Bristol Myers Squibb nor Karuna Therapeutics undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made and readers are cautioned not to place undue reliance on such statements.

Use of Non-GAAP Financial Information and Financial Guidance

In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this communication that are calculated and presented in accordance with GAAP and are presented because management has evaluated the company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company’s baseline performance, supplement or enhance management, analysts and investors overall understanding of the company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods.

Non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because Bristol Myers Squibb believes they neither relate to the ordinary course of Bristol Myers Squibb’s business nor reflect Bristol Myers Squibb’s underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods.

Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

A reconciliation of the forward-looking non-GAAP measures presented in this communication is not provided due to the inherent difficulty in forecasting and quantifying items that are necessary for such reconciliation. Namely, we are not able to reliably predict the impact of specified items such as unwind of inventory purchase price adjustments, accelerated depreciation and impairment of property, plant and equipment and intangible assets and stock compensation resulting from acquisition-related equity awards, or currency exchange rates beyond the next twelve months. As a result, the reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is not available without unreasonable effort. In addition, Bristol Myers Squibb believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results. In addition, the non-GAAP financial guidance in this communication excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication.

Contacts

Bristol Myers Squibb

Media Inquiries:
Media: media@bms.com

Investors:
Investor Relations: investor.relations@bms.com

Karuna Therapeutics

Investors:
Alexis Smith
+1 (617) 352-9917
asmith@karunatx.com


 EX-101.SCH 3 bmy-20231222.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20231222_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20231222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Common Stock [Member] Class of Stock [Domain] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name 1.000% Notes due 2025 [Member] 1.750% Notes due 2035 [Member] Celgene Contingent Value Rights [Member] EX-101.PRE 6 bmy-20231222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Dec. 22, 2023
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 22, 2023
Entity File Number 001-01136
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Central Index Key 0000014272
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One Route 206 & Province Line Road
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08543
City Area Code 609
Local Phone Number 252-4621
Entity Emerging Growth Company false
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
XML 8 ef20017313_8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2023-12-22 2023-12-22 0000014272 us-gaap:CommonStockMember 2023-12-22 2023-12-22 0000014272 bmy:One000NotesDue2025Member 2023-12-22 2023-12-22 0000014272 bmy:One750NotesDue2035Member 2023-12-22 2023-12-22 0000014272 bmy:CelgeneContingentValueRightsMember 2023-12-22 2023-12-22 false 0000014272 NYSE NYSE NYSE NYSE 8-K 2023-12-22 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 Route 206 & Province Line Road Princeton NJ 08543 609 252-4621 false true false false Common Stock, $0.10 Par Value BMY 1.000% Notes due 2025 BMY25 1.750% Notes due 2035 BMY35 Celgene Contingent Value Rights CELG RT false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " #O@99799!YDAD! #/ P $P M @ '($P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" 2 %%0 ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 5 22 1 false 4 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bmy-20231222.xsd bmy-20231222_def.xml bmy-20231222_lab.xml bmy-20231222_pre.xml ef20017313_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20017313_8k.htm": { "nsprefix": "bmy", "nsuri": "http://bms.com/20231222", "dts": { "schema": { "local": [ "bmy-20231222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "bmy-20231222_def.xml" ] }, "labelLink": { "local": [ "bmy-20231222_lab.xml" ] }, "presentationLink": { "local": [ "bmy-20231222_pre.xml" ] }, "inline": { "local": [ "ef20017313_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 3, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 6 }, "contextCount": 5, "entityCount": 1, "segmentCount": 4, "elementCount": 37, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 31 }, "report": { "R1": { "role": "http://bms.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231222to20231222", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20017313_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231222to20231222", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20017313_8k.htm", "first": true, "unique": true } } }, "tag": { "bmy_CelgeneContingentValueRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20231222", "localname": "CelgeneContingentValueRightsMember", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Celgene Contingent Value Rights [Member]" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsLineItems", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "bmy_One000NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20231222", "localname": "One000NotesDue2025Member", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsTable", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "bmy_One750NotesDue2035Member": { "xbrltype": "domainItemType", "nsuri": "http://bms.com/20231222", "localname": "One750NotesDue2035Member", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001140361-23-059159-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-059159-xbrl.zip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�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�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end